Abstract 1905P
Background
Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that form postnatally in non-lymphoid tissues and arise under physiological conditions. However, the clinical and immunological implications of heterogeneous subpopulations of TLS in clear cell renal cell carcinoma (ccRCC) remain to be elucidated.
Methods
H&E, immunohistochemistry and 12-marker multispectral fluorescent were used to evaluate the spatial location and maturation status of TLS with TME cell-infiltrating characterizations. We comprehensively assessed the prognostic value of TLS heterogeneity in 395 patients with ccRCC from two independent cohorts using log-rank tests, Cox hazards models, and scoring nomograms. Associations between TLS heterogeneity and immunologic activity of TME were assessed using quantified lymphocytes infiltration fraction.
Results
By pathological review, TLS were identified in 34.2% of the ccRCC samples. For ccRCC patients, the presence of intratumoral TLS markedly correlated with both superior progression-free survival (PFS) and overall survival (OS), while the peritumoral TLS exerted the opposite predictive trend of clinical outcomes. Multivariate Cox analysis revealed that the presence of intratumoral TLS was prominently correlated with better outcomes. Additionally, the novel nomograms incorporating the presence of intratumoral TLS prominently predicted the probability of 8-year PFS and OS of ccRCC (AUC >0.80). Moreover, a higher proportion of early TLS was found in peritumoral TLS (P=0.016), while intratumoral TLS were mainly composed of secondary follicle-like TLS (P=0.004). Interestingly, in ccRCC samples with the presence of peritumoral TLS enriched with primary follicle-like TLS, the proportion of PD-L1+ tumor-associated macrophages and Treg infiltration in the stroma were prominently increased, showing a typical suppressive tumor immune microenvironment.
Conclusions
In conclusion, this study revealed the predictive value of TLS heterogeneity on the progression and immunological responses of ccRCC for the first time. The intratumoral TLS could be used to assess both the prognostic patterns and the unique TME characteristics of each patient.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2375P - Neoadjuvant sintilimab combined with gemcitabine and cisplatin (GP) for muscle-invasive bladder cancer (MIBC) patients followed by selective bladder sparing surgery
Presenter: Zhou Tong
Session: Poster session 23
2376P - Pembrolizumab monotherapy following tri-modality treatment for selected patients with muscle-invasive bladder cancer
Presenter: Shang Bin Qin
Session: Poster session 23
2378P - Efficacy and safety outcomes with pembrolizumab (pembro) rechallenge for patients (pts) with advanced/metastatic urothelial cancer (UC) who responded to first-course treatment
Presenter: Vadim Koshkin
Session: Poster session 23
2379P - AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
Presenter: Philippe Barthélémy
Session: Poster session 23